Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hematological markers of prostate cancer risk

Key clinical point: Certain hematological parameters may predict the risk for prostate cancer in primary care.

Major finding: Higher red blood cell (hazard ratio [HR] per 1 standard deviation [SD] increase, 1.09; 95% confidence interval [CI], 1.05-1.13) and platelet counts (HR per 1 SD increase, 1.07; 95% CI, 1.04-1.11) were associated with an increased risk for prostate cancer. Higher white blood cell count (HR per 1 SD increase, 1.14; 95% CI, 1.05-1.24) and neutrophil count (HR per 1 SD increase, 1.27; 95% CI, 1.09-1.48) were associated with prostate cancer mortality.

Study details: The study analyzed complete blood counts of 209,686 men from the UK Biobank without a cancer diagnosis at baseline. Of these, 5,723 men were diagnosed with prostate cancer after a follow-up of 6.8 years.

Disclosures: Data analysis for the study was supported by Cancer Research UK grants. E Watts was supported by the Nuffield Department of Population Health Early Career Research Fellowship. The authors declared no conflicts of interest.


Watts EL et al. Cancer Epidemiol Biomarkers Prev. 2020 May 26. doi: 10.1158/1055-9965.EPI-19-1525.